Answers are grounded in this paper and cite their sources.
Demonstrates enhanced dissolution and lipid-lowering efficacy of solidified rosuvastatin nanoemulsions in hyperlipidemic rats, indicating improved oral bioavailability of poorly soluble drugs.
The present work focuses on preparing a solidified self nano-emulsifying drug-delivery system (S-SNEDDS) to improve the in vitro dissolution of rosuvastatin and to evaluate its antihyperlipidemic activity. Powder flow characterization demonstrated good flow properties. The drug-excipient compatibility study indicates no possible interaction. Transmission electron microscopy and scanning electron microscopy revealed nonaggregated, spherical nanosized globules. The globule-size analysis revealed droplet size in nanorange (∼100 nm). S-SNEDDS exhibited improved drug release (∼95%) as compared with rosuvastatin powder (51.89%) at 60 min. Upon antihyperlipidemic study, S-SNEDDS after 14th day of treatment revealed significant reduction in cholesterol (33.47%), triglycerides (40.77%) and atherogenic index (81.28%), while high-density lipoprotein (118.43%) was increased. The study indicates the great potential of S-SNEDDS for improving oral absorption of such poorly soluble drugs and their pharmacodynamic efficacy.
No takes yet. Share an insight, caveat, or question.
Ahsan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: